Assay Detail
Binding
CHEMBL4828552
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method
36
Total Activities
36
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Cell Type | LNCaP |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Publication
Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 36 | 6.61 | 7.52 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4845915 | — | — | 1 | 7.52 |
| CHEMBL4856070 | — | — | 1 | 7.52 |
| CHEMBL4849023 | — | — | 1 | 7.40 |
| CHEMBL4870389 | — | — | 1 | 7.22 |
| CHEMBL4872533 | — | — | 1 | 7.16 |
| CHEMBL4847082 | — | — | 1 | 7.16 |
| CHEMBL1082407 | ENZALUTAMIDE | 4.0 | 1 | 7.12 |
| CHEMBL4852876 | — | — | 1 | 7.05 |
| CHEMBL4857183 | — | — | 1 | 7.00 |
| CHEMBL4870138 | — | — | 1 | 7.00 |
| CHEMBL4875734 | — | — | 1 | 7.00 |
| CHEMBL4876258 | — | — | 1 | 6.96 |
| CHEMBL4852991 | — | — | 1 | 6.89 |
| CHEMBL4871740 | — | — | 1 | 6.80 |
| CHEMBL4852542 | — | — | 1 | 6.77 |
| CHEMBL4849002 | — | — | 1 | 6.75 |
| CHEMBL4869391 | — | — | 1 | 6.75 |
| CHEMBL4866292 | — | — | 1 | 6.72 |
| CHEMBL4850974 | — | — | 1 | 6.72 |
| CHEMBL4856585 | — | — | 1 | 6.70 |
| CHEMBL4868944 | — | — | 1 | 6.64 |
| CHEMBL4877104 | — | — | 1 | 6.64 |
| CHEMBL4868764 | — | — | 1 | 6.62 |
| CHEMBL4864867 | — | — | 1 | 6.52 |
| CHEMBL4875909 | — | — | 1 | 6.30 |
| CHEMBL4871449 | — | — | 1 | 6.26 |
| CHEMBL4848581 | — | — | 1 | 6.18 |
| CHEMBL4854145 | — | — | 1 | 6.13 |
| CHEMBL4876467 | — | — | 1 | 5.82 |
| CHEMBL4877237 | — | — | 1 | 5.80 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4845915 | — | IC50 | = | 30.0 | nM | 7.52 |
| CHEMBL4856070 | — | IC50 | = | 30.0 | nM | 7.52 |
| CHEMBL4849023 | — | IC50 | = | 40.0 | nM | 7.40 |
| CHEMBL4870389 | — | IC50 | = | 60.0 | nM | 7.22 |
| CHEMBL4872533 | — | IC50 | = | 70.0 | nM | 7.16 |
| CHEMBL4847082 | — | IC50 | = | 70.0 | nM | 7.16 |
| CHEMBL1082407 | ENZALUTAMIDE | IC50 | = | 75.0 | nM | 7.12 |
| CHEMBL4852876 | — | IC50 | = | 90.0 | nM | 7.05 |
| CHEMBL4857183 | — | IC50 | = | 100.0 | nM | 7.00 |
| CHEMBL4870138 | — | IC50 | = | 100.0 | nM | 7.00 |
| CHEMBL4875734 | — | IC50 | = | 100.0 | nM | 7.00 |
| CHEMBL4876258 | — | IC50 | = | 110.0 | nM | 6.96 |
| CHEMBL4852991 | — | IC50 | = | 130.0 | nM | 6.89 |
| CHEMBL4871740 | — | IC50 | = | 160.0 | nM | 6.80 |
| CHEMBL4852542 | — | IC50 | = | 170.0 | nM | 6.77 |
| CHEMBL4849002 | — | IC50 | = | 180.0 | nM | 6.75 |
| CHEMBL4869391 | — | IC50 | = | 180.0 | nM | 6.75 |
| CHEMBL4850974 | — | IC50 | = | 190.0 | nM | 6.72 |
| CHEMBL4866292 | — | IC50 | = | 190.0 | nM | 6.72 |
| CHEMBL4856585 | — | IC50 | = | 200.0 | nM | 6.70 |
| CHEMBL4868944 | — | IC50 | = | 230.0 | nM | 6.64 |
| CHEMBL4877104 | — | IC50 | = | 230.0 | nM | 6.64 |
| CHEMBL4868764 | — | IC50 | = | 240.0 | nM | 6.62 |
| CHEMBL4864867 | — | IC50 | = | 300.0 | nM | 6.52 |
| CHEMBL4875909 | — | IC50 | = | 500.0 | nM | 6.30 |
| CHEMBL4871449 | — | IC50 | = | 550.0 | nM | 6.26 |
| CHEMBL4848581 | — | IC50 | = | 660.0 | nM | 6.18 |
| CHEMBL4854145 | — | IC50 | = | 740.0 | nM | 6.13 |
| CHEMBL4876467 | — | IC50 | = | 1500.0 | nM | 5.82 |
| CHEMBL4877237 | — | IC50 | = | 1590.0 | nM | 5.80 |
| CHEMBL4852702 | — | IC50 | = | 1650.0 | nM | 5.78 |
| CHEMBL4860114 | — | IC50 | = | 1900.0 | nM | 5.72 |
| CHEMBL4846981 | — | IC50 | = | 2170.0 | nM | 5.66 |
| CHEMBL4870661 | — | IC50 | = | 32000.0 | nM | 4.50 |
| CHEMBL4874089 | — | IC50 | - | — | - | |
| CHEMBL4847627 | — | IC50 | - | — | - |